# US 2018/0021439 A1 · Oligosaccharide conjugates and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021439 A1
- Document ID: US20180021439A1
- Status: Published application
- Kind: A1
- Application number: 15/662,699
- Filed: 2017-07-28
- Published: 2018-01-25
- Earliest claimed: 2013-04-16
- Assignees: The Secretary of State for Environment, Food and Rural Affairs; The Governors of the University of Alberta
- Applicants: The Secretary of State for Environment, Food and Rural Affairs; The Governors of the University of Alberta
- Inventors: John MCGIVEN; David BUNDLE; Laurence HOWELLS; Julie GUIARD; Vijaya Ganesh NARAYANASWAMY
- Web page: https://patentgrep.com/patent/US20180021439A1

## CPC

- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/50: the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/56911: {Bacteria}
- G01N 2333/23: from Brucella (G)
- G01N 2400/00: Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N 2400/10: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

There is provided a method of detecting in a sample the presence of an anti-M and/or anti-A and/or anti-C/Y antibody, the method comprising contacting the sample with a diagnostic conjugate provided according to the invention, comprising an oligosaccharide which comprises at least two units of 4,6-dideoxy-4-acylamido-α-pyranose and comprising at least one -(1-3)- link between adjacent 4,6-dideoxy-4-acylamido-α-pyranose units, in which the carbon at position 5 in the pyranose is linked to an R group, where R is independently selected from —CH2OH, —H or an alkyl group having at least one C atom, the oligosaccharide being covalently linked to a non-saccharide molecule or to a surface.

## Claims

### Claim 1

(canceled)

### Claim 2

A diagnostic conjugate comprising an oligosaccharide which comprises at least two units of 4,6-dideoxy-4-acylamido-α-pyranose and comprising at least one -(1-3)- link between adjacent 4,6-dideoxy-4-acylamido-α-pyranose units,
in which the carbon at position 5 in the pyranose is linked to an R group, where R is independently selected from —CH2OH, —H or an alkyl group having at least one C atom,
the oligosaccharide being covalently linked to a non-saccharide molecule or to a solid entity.

### Claim 3 (depends on 2)

The diagnostic conjugate according to claim 2 wherein the oligosaccharide comprises no more than one -(1-3)- link.

### Claim 4 (depends on 2)

The diagnostic conjugate according to claim 2, wherein the oligosaccharide consists of two, three or four 4,6-dideoxy-4-acylamido-α-pyranose units.

### Claim 5 (depends on 4)

The diagnostic conjugate according to claim 4 which is a specific M-antigen, capable of preferentially binding to an anti-M antibody.

### Claim at position 6

-8. (canceled)

### Claim 9 (depends on 2)

The diagnostic conjugate according to claim 2 wherein the oligosaccharide comprises at least six 4,6-dideoxy-4-acylamido-α-pyranose units.

### Claim 10 (depends on 9)

The diagnostic conjugate according to claim 9 which is a universal antigen, capable of binding to an anti-M antibody or to an anti-A antibody or to an anti-C/Y antibody.

### Claim 11 (depends on 2)

The diagnostic conjugate according to claim 2 wherein the oligosaccharide is selected from the group consisting of a disaccharide of Formula I, a trisaccharide of Formula III or IV, a tetrasaccharide of Formula VII, a hexasaccharide of Formula XIII or XIV, and a nonasaccharide of Formula XV; wherein Formula I is
4,6-dideoxy-4-acylamido-α-pyranosyl-(1-3)-4,6-dideoxy-4-acylamido-α-pyranose;
Formula III is 4,6-dideoxy-4-acylamido-α-pyranosyl-(1-3)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranose;
Formula IV is 4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-3)-4,6-dideoxy-4-acylamido-α-pyranose;
Formula VII is 4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-3)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranose;
Formula XIII is 4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-3)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranose;
Formula XIV is 4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-3)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranose;
and Formula XV is 4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-3)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranosyl-(1-2)-4,6-dideoxy-4-acylamido-α-pyranose.

### Claim 12

(canceled)

### Claim 13 (depends on 2)

The diagnostic conjugate according to claim 2 comprising an oligosaccharide which comprises at least six 4,6-dideoxy-4-acylamido-α-pyranose units and comprising overlapping tetrasaccharides of Formula VII, such that a third and fourth 4,6-dideoxy-4-acylamido-α-pyranose units in one tetrasaccharide form a first and second 4,6-dideoxy-4-acylamido-α-pyranose units in the next tetrasaccharide, to form an oligosaccharide in which the links between contiguous 4,6-dideoxy-4-acylamido-α-pyranose units are alternating -(1,2)- and -(1,3)- links;
in which the carbon at position 5 in the pyranose is linked to an R group, where R is independently selected from —CH2OH, —H or an alkyl group having at least one C atom.

### Claim 14 (depends on 2)

The diagnostic conjugate according to claim 2 comprising an oligosaccharide which comprises at least seven 4,6-dideoxy-4-acylamido-α-pyranose units and comprising overlapping tetrasaccharides of Formula VII, such that a fourth 4,6-dideoxy-4-acylamido-α-pyranose unit in one tetrasaccharide forms the a 4,6-dideoxy-4-acylamido-α-pyranose unit in the next tetrasaccharide;
in which the carbon at position 5 in the pyranose is linked to an R group, where R is independently selected from —CH2OH, —H or an alkyl group having at least one C atom.

### Claim 15 (depends on 2)

The diagnostic conjugate according to claim 2 wherein, in the oligosaccharide, R is methyl, ethyl or butyl.

### Claim 16

(canceled)

### Claim 17 (depends on 2)

The diagnostic conjugate according to claim 2 wherein at least one 4,6-dideoxy-4-acylamido-α-pyranosyl unit is 4,6-dideoxy-4-formamido-α-D-mannopyranosyl.

### Claim 18 (depends on 2)

The diagnostic conjugate according to claim 2, wherein the non-saccharide molecule is selected from the group consisting of a protein, Bovine Serum Albumin (BSA), a non-protein carrier molecule comprising hydrophobic elements, and a fluorophore.

### Claim 19 (depends on 2)

The diagnostic conjugate according to claim 2, wherein the oligosaccharide is linked to a solid entity via a protein, via Bovine Serum Albumin (BSA), or via hydrazone conjugation.

### Claim at position 18

-35. (canceled)

### Claim 36 (depends on 2)

A kit comprising a diagnostic conjugate according to claim 2 and further comprising means for obtaining and/or containing a biological sample from an animal, and/or one or more laboratory reagents useful for conducting an antibody-antigen binding detection assay, and/or packaging materials and/or materials providing instructions for use of the kit.

### Claim at position 20

-43. (canceled)
